Santen Pharmaceutical Launches Verkazia In China For Severe Childhood VKC Treatment
I'm PortAI, I can summarize articles.
Santen Pharmaceutical Co., Ltd. has launched Verkazia (Ciclosporin Eye Drops III) in China to treat severe vernal keratoconjunctivitis (VKC) in children and young adults. This preservative-free eye drop aims to improve patients' quality of life by reducing inflammation. Verkazia is already available in 11 countries, including France and the UK. Santen's stock closed at $10.37 on December 22, unchanged from the previous session.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments